Prof Jean-François Dufour, Switzerland sheds lights on this important question.
The PanNASH initiative is led by an international, multidisciplinary expert committee
- Medical experts in areas related to NASH such as hepatology, diabetes, and cardiology
- Scientific experts focused on promoting a better understanding of the pathophysiological mechanisms involved in NASH
It is estimated that 25% of the global adult population is potentially affected by non-alcoholic fatty liver disease (NAFLD), with the highest prevalence in the Middle East and South America and the lowest in Africa.
Liver biopsy studies suggest that fibrosis progresses at a rate of approximately one stage per decade, suggesting that stage 2 fibrosis will progress to cirrhosis within 20 years.
NAFLD and NASH are substantial public health and economic burden.
Type 2 diabetes mellitus (T2DM) is present in about 23% of NAFLD patients and about 44% of NASH patients.(7) Moreover, NAFLD oftentimes precedes T2DM.